Will New Medication Guidelines For Rheumatoid Arthritis Improve Patient Satisfaction With Treatment?
By Kathleen Hoffman, PhD, MSPH|2021-10-05T08:01:41-05:00October 5th, 2021|Patient insights, Marketing|0 Comments
Will New Medication Guidelines For Rheumatoid Arthritis Improve Patient Satisfaction With Treatment? By Kathleen Hoffman, PhD, MSPH Despite the advances and diversification of disease modifying antirheumatic drugs (DMARDs) to treat rheumatoid arthritis (RA), a recent report surveying current RA patients showed that the majority are not satisfied with their treatment experience. In a study of 258 patients, all of whom were taking at least 1 DMARD, only [...]
What Are Patients and Caregivers Talking About? Lung Cancer Biomarkers
By Kathleen Hoffman, PhD, MSPH|2021-09-28T08:27:58-05:00September 28th, 2021|Marketing, Clinical trials, HEOR, Patient engagement, Patient insights|0 Comments
What Are Patients and Caregivers Talking About? Lung Cancer Biomarkers By Kathleen Hoffman, PhD, MSPH Since the FDA approved the first targeted treatment for NSCLC in 2003, treatment decisions for NSCLC are increasingly made based on individual genomics.1,2Â There are now 20 distinct biomarkers that serve as identification points differentiating cancer cells from healthy cells and distinguishing one expression of cancer from another. Science has progressed from [...]
Impressive Advances in Treating Chronic Lymphocytic Leukemia
By Kathleen Hoffman, PhD, MSPH|2021-09-21T11:29:08-05:00September 21st, 2021|Patient communities, Patient insights|0 Comments
Impressive Advances in Treating Chronic Lymphocytic Leukemia By Kathleen Hoffman, PhD, MSPH Chronic Lymphocytic Leukemia (CLL) is the most prevalent form of adult leukemia, with about 20,000 new diagnoses per year in the United States alone.1Â While it can occur at earlier ages, it is primarily a disease of older adults, with 70 years as the average age at diagnosis. Most of those who are diagnosed have [...]
Undertreated Psoriasis Patients Need Answers
By Kathleen Hoffman, PhD, MSPH|2021-09-14T08:48:01-05:00September 14th, 2021|Patient communities, Patient insights|0 Comments
Undertreated Psoriasis Patients Need Answers By Kathleen Hoffman, PhD, MSPH A 2021 study concluded that psoriasis continues to be a common inflammatory disease, affecting more than 7.5 million adults in the US alone --Â 3.0% of the US adult population.1Â By far the most common form (80% of cases)2 is plaque psoriasis, which intermittently creates patches of scaly and itchy skin, often on the scalp, knees, or [...]
Born Since 1990? Your Risk of Colorectal Cancer Just Went Up
By Kathleen Hoffman, PhD, MSPH|2021-08-31T10:04:59-05:00August 31st, 2021|Patient communities, Marketing|0 Comments
Born Since 1990? Your Risk of Colorectal Cancer Just Went Up By Kathleen Hoffman, PhD MSPH The age at which people at average risk of colon cancer should start being screened used to be 50.2 In May 2021, the U.S. Preventive Services Task Force lowered it to 45. It’s been lowered because the age at which people are being diagnosed with colorectal cancer (CRC) is going down [...]
Positive News for Triple Negative Breast Cancer
By Kathleen Hoffman, PhD, MSPH|2021-08-24T08:44:15-05:00August 24th, 2021|Patient communities, Patient insights|0 Comments
Positive News For Triple Negative Breast Cancer By Kathleen Hoffman, PhD, MSPH Almost 150,000 patients and caregivers have interest in, have joined communities, have searched and posted about breast cancer and advanced breast cancer on Inspire. Almost 22,000 posts have been written about breast cancer research. There has been intense interest in finding medications that can penetrate the 10-20% of breast cancers that don’t respond to the [...]
The Life Changing Diagnosis of Inflammatory Bowel Disease
By Kathleen Hoffman, PhD, MSPH|2021-08-17T08:25:56-05:00August 17th, 2021|Patient communities, Marketing|0 Comments
The Life Changing Diagnosis of Inflammatory Bowel Disease By Kathleen Hoffman, PhD MSPH ​​ I've had UC for 4 years also. Diagnosed with a colonoscopy after 5 months of diarrhea, losing 1/3rd of my otherwise normal weight and enough blood to require a 2-pint transfusion. Pausing a conversation to use the restroom is biologically necessary, but can be socially awkward. People living with inflammatory bowel diseases (IBD) [...]
“I need to breathe” — Living with Asthma: Patient Experiences, Old Challenges, New Drugs
By Kathleen Hoffman, PhD, MSPH|2021-08-10T08:08:56-05:00August 10th, 2021|Patient communities, Patient insights|0 Comments
"I need to breathe" — Living with Asthma: Patient Experiences, Old Challenges, New Drugs By Kathleen Hoffman, PhD MSPH Earlier this month, the American Lung Association (ALA), Inspire’s partner for the “Living with Asthma” online community, announced that it is looking for patient panelists to participate in a PFDD (Patient-Focused Drug Development) meeting on Pediatric Asthma, to be held virtually on 9/20/2021. “The meeting will consist [...]
Out of Nowhere: Kidney Cancer
By Kathleen Hoffman, PhD, MSPH|2021-08-03T08:22:22-05:00August 3rd, 2021|Patient communities, Patient insights|0 Comments
Out of Nowhere: Kidney Cancer By Kathleen Hoffman, PhD MSPH Of the estimated 1.9 million cancers diagnosed each year in the US, around 4 percent are kidney cancers, the most common are renal cell carcinomas (RCC). Around 76,000 new cases will occur in the US in 2021, 48,0000 in men and 27,000 in women. Kidney cancer can occur at any age, but is most likely to [...]
New Treatments Create Buzz Among Patients with Prostate Cancer and their Caregivers
By Kathleen Hoffman, PhD, MSPH|2021-07-27T09:07:47-05:00July 27th, 2021|Patient insights, Clinical trials|0 Comments
New Treatments Create Buzz Among Patients with Prostate Cancer and their Caregivers By Kathleen Hoffman, PhD MSPH Prostate cancer is highly treatable in its early stages, much less so once it has metastasized, where the five-year survival rate is below 30%. In search of more treatment options, a patient with advanced prostate cancer wrote on Inspire: I was diagnosed with prostate cancer in [date]. Have done virtually every [...]